Wall Street Zen lowered shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) from a sell rating to a strong sell rating in a research report report published on Saturday morning,Wall Street Zen reports.
Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Thursday, October 15th. Robert W. Baird lowered shares of Contineum Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $19.00 to $14.00 in a research report on Tuesday, October 13th. Morgan Stanley decreased their price target on shares of Contineum Therapeutics from $18.00 to $17.00 and set an “equal weight” rating for the company in a report on Monday, September 28th. Stifel Nicolaus set a $23.00 price target on Contineum Therapeutics in a research report on Wednesday, November 4th. Finally, Royal Bank Of Canada raised their price target on Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $21.40.
Check Out Our Latest Stock Analysis on CTNM
Contineum Therapeutics Stock Down 1.9%
Shares of Contineum Therapeutics stock opened at $9.67 on Friday. Contineum Therapeutics has a 12-month low of $6.72 and a 12-month high of $17.78. The stock has a 50 day moving average price of $11.14 and a two-hundred day moving average price of $13.38.
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). On average, analysts predict that Contineum Therapeutics will post -1.76 EPS for the current fiscal year.
Institutional Trading of Contineum Therapeutics
Several institutional investors have recently made changes to their positions in CTNM. Janus Henderson Group PLC increased its stake in Contineum Therapeutics by 11.7% in the first quarter. Janus Henderson Group PLC now owns 2,734,836 shares of the company’s stock valued at $35,594,000 after acquiring an additional 285,857 shares during the period. Versant Venture Management LLC raised its position in Contineum Therapeutics by 138.2% in the third quarter. Versant Venture Management LLC now owns 1,292,628 shares of the company’s stock worth $17,347,000 after purchasing an additional 750,000 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Contineum Therapeutics by 51.6% during the third quarter. Goldman Sachs Group Inc. now owns 753,900 shares of the company’s stock worth $10,117,000 after purchasing an additional 256,645 shares during the period. Integral Health Asset Management LLC bought a new position in Contineum Therapeutics during the third quarter worth about $4,630,000. Finally, HighVista Strategies LLC bought a new position in Contineum Therapeutics during the third quarter worth about $2,923,000.
Contineum Therapeutics Company Profile
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.
Further Reading
- Five stocks we like better than Contineum Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
